Tim Robinson Appointed Chair of the Board at Single Use Support

Single Use Support welcomes Tim Robinson as its new Chairman of the Board. His appointment marks another significant step in strengthening the company’s leadership and strategic direction as it continues to scale in the biopharma industry.

Kufstein, July 22, 2025 - Tim Robinson joins Single Use Support as Chair of the Board, bringing with him a wealth of leadership experience and a proven ability to guide companies through transformative growth. In this role, he will help shape the strategic direction of the company, working closely with the Board, CEO, and Executive Team to ensure strong alignment and effective decision-making. Tim will also play a key role in fostering shareholder engagement and providing seasoned counsel to the leadership team. Single Use Support is majority-owned by Novo Holdings, whose backing reinforces the company’s long-term growth ambitions. 

His collaborative mindset and deep industry expertise will be most valuable in driving Single Use Support’s mission to deliver cutting-edge solutions to the biopharma sector. “We’re excited to leverage Tim’s deep strategic insights and wide-ranging expertise within the Single Use Support team,” said Darren Verlenden, CEO. “His leadership will be instrumental as we continue to scale and pioneer transformative single-use fluid management solutions in the biopharmaceutical industry.”

Tim brings decades of international leadership experience across the technology and life sciences sectors. With a background in physiology & biochemistry, he began his career at IBM before holding senior roles at Silicon Graphics and Thales. He later served as CEO of several private equity-backed companies, most notably leading LGC through a decade of transformative growth into a global life science tools provider. Tim will continue to serve as Lead Non-Executive Board Member at the UK Government’s Home Office and as a Trustee of Place2Be, a charity supporting children’s mental health.

His appointment marks a significant milestone in Single Use Support's journey to expand its presence in the biopharmaceutical sector.